Compare CRSP & WFG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRSP | WFG |
|---|---|---|
| Founded | 2013 | 1955 |
| Country | Switzerland | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 4.6B |
| IPO Year | 2016 | N/A |
| Metric | CRSP | WFG |
|---|---|---|
| Price | $50.24 | $76.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 3 |
| Target Price | $71.95 | ★ $93.00 |
| AVG Volume (30 Days) | ★ 1.8M | 278.0K |
| Earning Date | 02-11-2026 | 02-11-2026 |
| Dividend Yield | N/A | ★ 1.78% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $38,337,000.00 | ★ $5,702,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,376.73 | $9.45 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $30.04 | $57.34 |
| 52 Week High | $78.48 | $86.88 |
| Indicator | CRSP | WFG |
|---|---|---|
| Relative Strength Index (RSI) | 40.76 | 74.48 |
| Support Level | $49.10 | $67.73 |
| Resistance Level | $53.00 | $71.22 |
| Average True Range (ATR) | 3.12 | 2.10 |
| MACD | -0.48 | 0.21 |
| Stochastic Oscillator | 12.40 | 95.67 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
West Fraser Timber is a softwood lumber company that also produces wood panels and pulp products. The company produces its wood products globally, with lumber mills in British Columbia, Alberta, Europe, and the Southeastern United States. Following its acquisition of Norbord in 2021, West Fraser is one of the largest oriented strand board producers in the world.